Apogee therapeutics announces positive interim results from the phase 1b trial of apg808, its novel half-life extended il-4rΑ antibody, in patients with mild-to-moderate asthma

Multiple doses of apg808 resulted in rapid suppression of feno, a biomarker of type 2 inflammation associated with exacerbations in asthma, with a robust maximal feno decrease from baseline of 53%

APG Ratings Summary

APG Quant Ranking